Kensington Investment Counsel LLC Sells 7,293 Shares of TransMedics Group, Inc. $TMDX

Kensington Investment Counsel LLC reduced its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 46.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,291 shares of the company’s stock after selling 7,293 shares during the period. Kensington Investment Counsel LLC’s holdings in TransMedics Group were worth $824,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of TMDX. Goldman Sachs Group Inc. lifted its stake in TransMedics Group by 50.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of TransMedics Group by 54.2% in the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after buying an additional 223,409 shares during the period. Wellington Management Group LLP lifted its position in shares of TransMedics Group by 100.5% during the 4th quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock valued at $52,713,000 after buying an additional 217,180 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock valued at $69,338,000 after buying an additional 171,810 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after acquiring an additional 113,817 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on TMDX shares. TD Cowen restated a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday, July 1st. Weiss Ratings lowered shares of TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Stifel Nicolaus raised their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Finally, Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $129.55.

TransMedics Group Trading Up 2.2%

Shares of TMDX opened at $78.00 on Thursday. The business’s 50-day moving average price is $72.26 and its 200-day moving average price is $101.42. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The stock has a market cap of $2.70 billion, a PE ratio of 17.73 and a beta of 1.89. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. During the same period in the previous year, the company posted $0.70 earnings per share. The company’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, equities analysts forecast that TransMedics Group, Inc. will post 1.88 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.